Zydus Saroglitazar shows positive Phase 3 results in rare liver disease PBC, US filing planned in 2026

Zydus Therapeutics reveals encouraging outcomes from Saroglitazar's clinical trial. The drug targets Primary Biliary Cholangitis. The EPICS-III trial demonstrates improved liver function in patients. These patients did not respond to standard treatment. Zydus plans to seek US regulatory approval in early 2026. Saroglitazar is a novel treatment option. It addresses bile acid toxicity and liver inflammation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vjFK0CD
via IFTTT